Taxane therapies are well-established, widely used, and effective anti-cancer treatments, representing an important component of the standard of care for many different cancers. However, as treatments, taxanes continue to have serious limitations both in terms of how they are administered (which necessitates regular unpleasant visits to the hospital) and the wide range of often serious toxicities they cause. Overcoming these limitations could have an enormously positive impact on the lives of the hundreds of thousands of cancer patients who are prescribed taxanes every year.

Modra is dedicated to addressing these challenges, and to applying its proprietary approach to improve taxane treatments for these patients. The company’s lead program, ModraDoc006/r, is being developed to transform the experience of docetaxel therapy. For the large patient populations that would benefit, this novel oral therapy would be effective in fighting tumors, could be taken at home, and would offer a substantially better safety and tolerability profile.

Access our most recent press releases and news here